Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (51-60 of 356) with videos related to

Pageof 36
Sort By:
American Journal of Respiratory and Critical Care Medicine|July 9, 2011
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosisPaul W Noble, Luca Richeldi, Naftali Kaminski
Annals of Translational Medicine|January 13, 2021
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don'tGiacomo Sgalla, Pier-Valerio Mari, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|August 26, 2017
Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary FibrosisMark G Jones, Giacomo Sgalla, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|February 8, 2022
The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?Giacomo Sgalla, Marlies S Wijsenbeek, Luca Richeldi
The New England Journal of Medicine|August 24, 2022
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. ReplyLuca Richeldi, Susanne Stowasser, Toby M Maher
The European Respiratory Journal|September 8, 2018
Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societiesLuca Richeldi, Kevin C Wilson, Ganesh Raghu
Respirology (Carlton, Vic.)|October 6, 2017
Managing patients with interstitial lung disease: Two more pieces of the puzzleFrancesco Macagno, Paolo Maria Leone, Luca Richeldi
Respiration; International Review of Thoracic Diseases|December 4, 2013
Idiopathic pulmonary fibrosis: recent trials and current drug therapyMark G Jones, Sophie Fletcher, Luca Richeldi
Lung India : Official Organ of Indian Chest Society|March 9, 2021
Post-COVID lung fibrosis: The tsunami that will follow the earthquakeZarir F Udwadia, Parvaiz A Koul, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|August 8, 2009
To BAL or not to BAL: is this a problem in diagnosing IPF?Paolo Spagnolo, Fabrizio Luppi, Giulio Rossi, et al.
Pageof 36

Showing results (51-60 of 356) with videos related to

Sort By:
Pageof 36
American Journal of Respiratory and Critical Care Medicine|July 9, 2011
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosisPaul W Noble, Luca Richeldi, Naftali Kaminski
Annals of Translational Medicine|January 13, 2021
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don'tGiacomo Sgalla, Pier-Valerio Mari, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|August 26, 2017
Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary FibrosisMark G Jones, Giacomo Sgalla, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|February 8, 2022
The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?Giacomo Sgalla, Marlies S Wijsenbeek, Luca Richeldi
The New England Journal of Medicine|August 24, 2022
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. ReplyLuca Richeldi, Susanne Stowasser, Toby M Maher
The European Respiratory Journal|September 8, 2018
Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societiesLuca Richeldi, Kevin C Wilson, Ganesh Raghu
Respirology (Carlton, Vic.)|October 6, 2017
Managing patients with interstitial lung disease: Two more pieces of the puzzleFrancesco Macagno, Paolo Maria Leone, Luca Richeldi
Respiration; International Review of Thoracic Diseases|December 4, 2013
Idiopathic pulmonary fibrosis: recent trials and current drug therapyMark G Jones, Sophie Fletcher, Luca Richeldi
Lung India : Official Organ of Indian Chest Society|March 9, 2021
Post-COVID lung fibrosis: The tsunami that will follow the earthquakeZarir F Udwadia, Parvaiz A Koul, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|August 8, 2009
To BAL or not to BAL: is this a problem in diagnosing IPF?Paolo Spagnolo, Fabrizio Luppi, Giulio Rossi, et al.
Pageof 36